Longevity Startups

Vitaliti is developing a therapeutic exercise mimetic intended to restore the ability to gain the benefits of exercise for people with cardiopulmonary disease. The company targets patients with debilitating cardiopulmonary conditions.

1 investor

Vitality Blueprint analyzes bloodwork through a performance lens to identify physiological constraints and deliver personalized protocols for enhancing athletic and physical performance. The platform serves elite athletes and performance coaches, interpreting biomarkers using published science rather than generic AI.

1 investor

XO Technology builds the XO Companion Ring, a wearable device that automates health assessments and provides real-time insights for caregivers. It is aimed at senior care facilities to monitor the health and wellness of aging individuals.

1 investor

YEARS operates a physician-led healthspan clinic focused on preventive medicine, using standardized diagnostic protocols and biomarkers to detect age-related disease risks early and recommend personalized lifestyle and medical interventions. It serves individual health customers seeking longitudinal monitoring and prevention rather than reactive treatment.

1 investor

Yosemite is working toward making cancer non-lethal, focusing on cancer research and treatment.

1 investor

Zylem Biosciences develops Metabolic Redox Modulators (MRMs), a patented platform of drug candidates targeting the SR-B1 receptor to treat cancer, cardiovascular disease, and other age-related conditions. The company leverages fifteen years of research from Northwestern University to create therapeutics that induce metabolic dysfunction in disease cells while sparing healthy cells.

1 investor

Kolagen Pharma develops and sells pharmaceuticals, medical devices, and research reagents, and manufactures cosmetics, focusing on collagen-based biomaterials for regenerative medicine. Founded by university researchers in science and pharmacology, it is based within Kyoto University's medical research facilities in Japan.

1 investor

Shanghai Cell Therapy Group develops cell-therapy technologies and products aimed at curative treatment of tumors and aging-related diseases, including CAR-T therapies such as a non-lymphodepleting three-target CAR-T and a PD1 nanobody mesothelin-targeting CAR-T. The company also works on cell rejuvenation approaches to prevent and intervene in aging-related conditions, with operations in China.

1 investor

Carrier Biomed works on extracellular vesicles (exosomes), lipid-bilayer particles 30-150 nm in size carrying cell-specific nucleic acids, proteins, and other molecules. The company explores their use in disease diagnosis and treatment, regenerative medicine, and as drug-delivery vehicles for targeted therapy.

1 investor

Arktus Therapeutics develops regenerative medicine treatments derived from iPS cells, initially focusing on knee joint diseases with plans to expand to additional organ systems. The company brings together clinical, research, and regulatory expertise to advance innovative cell-based therapeutic products.

1 investor

MiraiSpeaker develops audio hardware products and assistive hearing technology for aging populations, enabling seniors to experience enriched lives through technology.

1 investor

Mirai Speaker (株式会社ミライスピーカー) plans, develops, manufactures, and sells age-tech audio products such as the "Mirai Speaker" and "Mirai Speaker Ear," aimed at making longer lifespans more comfortable through technology. The Tokyo-based company focuses on hearing-support devices for older adults.

1 investor

Soiken Holdings is a biotech venture originating from Osaka University's medical faculty that develops and commercializes biomarker technologies and systems for objective health assessment across food, pharmaceutical, and healthcare applications.

1 investor

NeuExcell Therapeutics is a clinical-stage biopharmaceutical company developing neuro-regenerative therapies for neurodegenerative diseases and nerve injuries, with trials targeting glioma, Alzheimer's disease, and stroke. Its technology converts supportive glial cells into functional neurons for in-situ repair of damaged brain tissue.

1 investor

AION Healthspan develops investigational cell-based and molecular therapies aimed at preventing, delaying, and reversing chronic, metabolic, and autoimmune conditions associated with aging. Building on research from the University of Miami's Diabetes Research Institute and Cell Transplant Center, the company works in regenerative medicine to extend healthy lifespan.

0 investors

Alkahest uses proteomics data and advanced computational methods to understand disease mechanisms, identify drug targets, and discover biomarkers for therapeutic development, with a focus on aging-related diseases like Parkinson's and Alzheimer's.

0 investors

Amberstone develops tumor-activated immunotherapeutics using its T-MATE technology, which conditionally activates immune responses within tumors while sparing healthy tissue. The approach targets historically difficult or toxic cancer targets that traditional immunotherapies cannot safely address.

0 investors

Ankasa is developing ART352-L, a regenerative medicine designed to enhance bone formation in reconstructive surgeries, with initial focus on spinal fusion procedures to treat degenerative disc disease. The therapy aims to improve healing outcomes and reduce revision surgeries for patients requiring bone reconstruction.

0 investors

AptamiR Therapeutics is a US biotechnology company in pre-clinical development of microRNA-based oligonucleotide therapeutics (antagomirs), including miR-22-3p drug candidates for cardiometabolic disorders such as obesity, diabetes and fatty liver disease (MAFLD/MASH) and candidates for epithelial ovarian cancer. Its approach modulates multiple target genes simultaneously to address complex metabolic diseases and cancer.

0 investors

Arcadia Communities develops and operates senior living communities offering Independent Living, Assisted Living, and Memory Care for seniors. The privately owned company runs communities in Michigan, Kentucky, Florida, and Tennessee in the United States.

0 investors

AscentX Medical develops injectable regenerative therapy using autologous tissue engineering with microspheres to restore soft tissue function, targeting the aging population and patients in clinical settings. The company is also launching cGMP aseptic fill and finish contract manufacturing (CMO) services for the pharmaceutical and medical device industries.

0 investors

Atlee Biotech develops novel treatments for acute disorders. The company focuses on therapeutics aimed at improving health and longevity.

0 investors

BioAegis Therapeutics is a clinical-stage biotech developing therapies for infectious and non-infectious inflammatory diseases based on a recombinant human form of plasma gelsolin (rhu-pGSN), a blood protein that regulates the immune response. Its platform aims to restore depleted gelsolin levels to control inflammation without suppressing immune function.

0 investors

BioRegenx develops hardware and software for microscopy imaging of the endothelial glycocalyx, along with microvascular regenerative products, serving doctors, research scientists, and wellness consumers. The company combines diagnostic imaging technology with regenerative therapeutics in the medical device and wellness sector.

0 investors